Amgen Inc. (AMGN) News
Follow Amgen Inc. (AMGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 98 public stories across 48 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Amgen (AMGN) reports Q3: everything you need to know ahead of earnings
Biotech company Amgen NASDAQ:AMGNwill be reporting results this Tuesday after market hours. Here’s what you need to know.Amgen beat analysts’ revenue expectations last quarter, reporting revenues of $10.05 billion, up 9.
EQUITY | Nov 02, 2026, 03:16 AM UTC
M
U.S. Stocks Face AI Concerns as Investors Watch Midterms, Earnings and Jobs Data
The weekly market preview highlights AI-related stock weakness and upcoming U.S. midterm elections, earnings and employment data.
EQUITY | Nov 01, 2026, 10:11 PM UTC
M
OpenAI Launches Biology AI, Restricts Access to Approved Labs
OpenAI launched an AI for biology that answers more high-risk queries and will make it available only to approved laboratories.
EQUITY | Nov 01, 2026, 04:33 AM UTC
M
Nasdaq Falls Nearly 3%, on Track for Worst Month Since Trump Trade War Began
The Nasdaq fell nearly 3% and was experiencing its worst month since the start of the Trump trade war.
EQUITY | Oct 31, 2026, 12:43 AM UTC
M
US Elections, Earnings and Jobs Data Loom for AI-Wary Stocks
A preview flags midterm elections, earnings and jobs data as coming events for an AI-wary stock market.
EQUITY | Oct 30, 2026, 09:32 PM UTC
M
Amgen Announces Dividend of R$ 0.325209295 per Unit
Amgen announced a fourth-quarter 2026 dividend of R$ 0.325209295 per unit.
EQUITY | Oct 29, 2026, 07:35 PM UTC
M
Amgen announces third-quarter results presentation
Amgen announced a presentation of its third-quarter results.
EQUITY | Oct 28, 2026, 09:12 PM UTC
M
FDA Warns Amgen Over Promotional Cancer Drug Video
The FDA admonished Amgen over a promotional video for a cancer drug.
REGULATION | Oct 28, 2026, 09:54 AM UTC
M
Amgen Declares $2.52 Per-Share Fourth-Quarter 2026 Dividend
Amgen said its board declared a $2.52 per-share dividend for the fourth quarter of 2026. Payment is scheduled for Dec. 11 to stockholders of record as of the close of business on Nov. [date truncated in source].
EQUITY | Oct 27, 2026, 10:28 PM UTC
L
FDA warns Amgen over colorectal cancer drug video
The FDA said a promotional video for an Amgen colorectal cancer drug was misleading.
REGULATION | Oct 27, 2026, 06:29 PM UTC
M
FDA Warns Amgen Over Misleading Cancer Drug Promotional Video
The FDA said an Amgen video promoting its colorectal cancer drug highlighted benefits but did not adequately disclose serious safety risks and patient limitations.
REGULATION | Oct 27, 2026, 06:25 PM UTC
M
FDA Orders Amgen to Cease Misleading Vectibix Promotions
The FDA ordered Amgen to stop misleading Vectibix promotional communications. The company faces seizure and injunction if violations are not corrected.
REGULATION | Oct 27, 2026, 05:36 PM UTC
L
FDA Says Amgen Vectibix Video Omits Material Risk Information
The FDA says the video omits information on risks including dermatologic toxicity, infusion reactions and pulmonary fibrosis.
REGULATION | Oct 27, 2026, 05:35 PM UTC
M
Amgen Q3'26 earnings preview: revenue estimate 10.08B USD
Amgen is scheduled to report Q3'26 results on November 03 after the market closes. Revenue is estimated at 10.08 billion USD and EPS at 5.79 USD.
EQUITY | Oct 27, 2026, 11:00 AM UTC
M
Amgen Says Imdelltra Combo Reduced Death Risk 58% in First-Line Lung Cancer
EQUITY | Oct 24, 2026, 02:36 PM UTC
M
Amgen Combination Therapy Cuts Death Risk 58% in Lung Cancer Trial
Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% versus Imfinzi alone in patients with extensive-stage small cell lung cancer, according to trial data presented at a medical meetin
EQUITY | Oct 24, 2026, 02:30 PM UTC
M
Wall Street Rises as Healthcare Stocks Rally and Oil Retreats
U.S. main indexes moved higher Tuesday, supported by a surge in healthcare stocks and softer oil prices, extending a recovery from last week's technology-led selloff. Brent crude slipped 1.1% after touching a five-month
EQUITY | Oct 20, 2026, 04:38 PM UTC
M
AstraZeneca-Amgen Drug Achieves 69% Remission in Esophageal Disease Trial
Amgen and AstraZeneca said their asthma drug reduced swallowing difficulties and achieved disease remission in 69% of patients with a chronic inflammatory esophageal disorder.
EQUITY | Oct 20, 2026, 01:00 PM UTC
H
US Stocks Slide as Hot CPI Lifts Yields and Rate-Hike Bets
September CPI rose 3.7% year over year, above the 3.6% forecast and up from 3.4% in August. By midday, the Nasdaq 100 was down 1.0%, the S&P 500 fell 0.7%, and the 2-year Treasury yield had risen 14 basis points to 4.93%
MACRO | Oct 14, 2026, 03:39 PM UTC
L
Amgen Price Target Raised to $500.00/Share From $450.00 by Scotiabank
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 03:06 PM UTC
L
Scotiabank maintains Sector Outperform rating on Amgen, $500 price target
Scotiabank maintained their Sector Outperform rating on Amgen's stock with a price target of $500.00.The price target implies an upside of 19.6% from the Sep 28 close of $418.13.Key takeaways from the analyst noteStrong
EQUITY | Sep 29, 2026, 02:56 PM UTC
L
Weekly Recap: OASIZ—301 dazodalibep meets ESSDAI and Topline lacks detail
Amgen Inc. (NASDAQ:AMGN) said Phase 3 OASIZ—301 met its primary ESSDAI endpoint at Week 48 with dazodalibep showing benefits by Week 4 and mostly mild—moderate AEs, lowering clinical risk for its Immunology and Inflammat
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Amgen Gains as Sjogren's Drug Clears Phase 3
Amgen NASDAQ:AMGN, the biotechnology company, said its experimental Sjogren's disease drug dazodalibep met the main goal of a Phase 3 trial. Shares rose about 0.2% to $406.85 at 11.14am ET time on Thursday. The trial new
EQUITY | Sep 24, 2026, 08:11 PM UTC
M
Amgen shares jump after Sjögren’s trial win; Citi flags open questions
Amgen (AMGN) said its experimental drug dazodalibep reduced disease intensity in late-stage moderate-to-severe systemic Sjögren’s disease, lifting shares up to ~5% on Tuesday. Citi flagged “open questions.”
EARNINGS | Sep 22, 2026, 06:05 PM UTC
M
Amgen autoimmune drug meets main goal in late-stage trial
Amgen said its experimental autoimmune drug met the main goal of reducing disease activity in a late-stage trial, with shares up 4% in morning trading.
EQUITY | Sep 22, 2026, 05:13 PM UTC
L
AMGN - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
AMGN - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
NEWS | Sep 22, 2026, 01:02 PM UTC
M
Amgen’s autoimmune drug meets main goal in late-stage trial
Amgen said its experimental autoimmune treatment met the main goal of reducing disease activity in a late-stage trial.
EQUITY | Sep 22, 2026, 01:00 PM UTC
M
Roche obesity drug shows blood sugar control and 15.5% weight loss
Roche said its experimental dual-acting obesity drug improved blood sugar control and drove an average 15.5% body-weight loss in a mid-stage trial in overweight or obese patients with type 2 diabetes.
EQUITY | Sep 22, 2026, 11:22 AM UTC
M
Amgen Q2 revenue tops $10B; IMDELLTRA + durvalumab advances
Amgen reported Q2 2026 revenue topping $10B, driven by six key drug groups. The update also cites Phase III progress for IMDELLTRA + durvalumab in ES—SCLC, a shorter infusion monitoring approach, an Opdivo biosimilar fil
EQUITY | Sep 21, 2026, 11:27 AM UTC
H
Bitcoin Tops $80,000, S&P 500 Slips as Yields Reclaim 5%: Stock Market Today
Bitcoin (CRYPTO: BTC) punched through $80,000 on Friday, driving a rally in crypto equities even as broader markets stalled under rising bond yields. Kansas City Fed President Jeffrey Schmid delivered a hawkish signal, d
LIVE | Sep 18, 2026, 05:22 PM UTC
M
Sling Therapeutics raises $123 million for thyroid eye disease late-stage trial
Sling Therapeutics said it raised $123 million to advance a late-stage trial of its experimental oral drug for thyroid eye disease.
EQUITY | Sep 16, 2026, 11:00 AM UTC
M
Bristol Myers, Ono sue Amgen to block Opdivo biosimilar
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court seeking to block Amgen’s proposed U.S. biosimilar of Opdivo.
EQUITY | Sep 15, 2026, 08:25 PM UTC
L
Bristol Myers sues Amgen over proposed Opdivo biosimilar
By Blake BrittainBristol Myers Squibb NYSE:BMY and Ono Pharmaceutical TSE:4528 have sued Amgen NASDAQ:AMGN in Delaware federal court, seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunoth
NEWS | Sep 15, 2026, 05:29 PM UTC
L
AMGN: Quarterly growth and pipeline advances set the stage for durable, innovation-driven expansion
Strong quarterly growth was driven by key products and robust pipeline progress, including landmark phase III results for IMDELLTRA and positive data for TEZSPIRE. Strategic focus remains on innovation, disciplined capit
NEWS | Sep 15, 2026, 04:31 PM UTC
L
HBA India Summit Calls For Leaders To Command The AI Shift
Hyderabad summit highlights AI, GCCs, commercial acumen and influence as India takes on a larger role in global healthcare leadershipThe Healthcare Businesswomen’s Association (HBA) India hosted the third edition of its
NEWS | Sep 15, 2026, 08:32 AM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
H
Bulls and Bears: GameStop, Marvell, Robinhood
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks ended the week lower despite a Friday rebound, as surging oil prices, rising Treasury
LIVE | Sep 12, 2026, 12:50 PM UTC
L
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street — WSJ
By David WainerThere is a strange paradox haunting healthcare investing right now.Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.Th
NEWS | Sep 12, 2026, 09:30 AM UTC
H
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback
The Nasdaq Composite Index NYSE:COMP climbed on Friday alongside major Wall Street indexes after the latest consumer inflation report came in largely in line with expectations. It closed +0.96% higher after jumping by ov
NEWS | Sep 11, 2026, 08:31 PM UTC
L
Amgen price target cut to $425 by HSBC
HSBC cut its Amgen rating to Hold from Buy and lowered its price target to $425.00 from $445.00, according to Benzinga via TradingView News.
EQUITY | Sep 10, 2026, 02:23 PM UTC
L
AMGEN to present at the Morgan Stanley 24th annual global healthcare conference
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
25 dividend stocks to watch as market sentiment turns negative
Dividend-paying stocks gained renewed momentum Wednesday as investors shifted toward safety amid a slide in broader market averages.The blue-chip Dow Jones Industrial Average TVC:DJI dropped to a new one-month low while
ENERGY | Sep 09, 2026, 04:51 PM UTC
L
Barclays analyst says outcome is worst for Amgen
A Barclays analyst, Emily Field, said the Novartis heart-disease drug announcement was “the worst possible outcome for Amgen,” adding it cast doubt on one of Amgen’s major drugs.
EQUITY | Sep 08, 2026, 09:30 PM UTC
M
Amgen-AstraZeneca Imdelltra plus Imfinzi improves survival in SCLC trial
Amgen said its Imdelltra targeted immunotherapy with AstraZeneca’s Imfinzi significantly improved overall survival in extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.
EQUITY | Sep 08, 2026, 08:26 PM UTC
H
Amgen slides after Novartis pelacarsen failure report
Amgen shares were down more than 9% and were on pace for its largest daily decrease since October 2000. The move followed Novartis’ announcement that pelacarsen failed to reduce cardiovascular event risk.
EQUITY | Sep 08, 2026, 06:20 PM UTC
H
What's Moving Markets Today? — WSJ
By Shradha DineshMajor stock indexes faced pressure on Tuesday with a fresh slate of geopolitical tensions weighing on investors. The Dow industrials are down about 1%. Meanwhile, quantum computing stocks are on the rise
GEOPOLITICS | Sep 08, 2026, 05:49 PM UTC
H
Stocks slip as Brent above $97 reignites rate-hike fears
U.S. stocks fell Tuesday as crude oil extended higher, pushing the 10-year Treasury yield above 4.8% and reviving bets the Federal Reserve could raise rates next week. The Dow led declines, while Amgen was the biggest dr
EARNINGS | Sep 08, 2026, 05:13 PM UTC
H
Amgen helps drag Dow lower as oil jumps on Saudi strikes
U.S. stocks fell to start the week, with the Dow down about 550 points (~1%). S&P 500 and Nasdaq were down less than 0.5%, as Amgen shares dropped and oil rose on Saudi strikes.
COMMODITIES | Sep 08, 2026, 04:29 PM UTC
M
AstraZeneca says Imfinzi and Imdelltra improved survival
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival for extensive-stage small-cell lung cancer patients in a late-stage trial.
EQUITY | Sep 08, 2026, 01:51 PM UTC
M
AstraZeneca/Amgen Imfinzi–Imdelltra combo improves survival goal
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial, meeting its main survival goal.
EQUITY | Sep 08, 2026, 01:14 PM UTC
L
AMGN Imdelltra plus Imfinzi shows improved overall survival
TradeXchange Newsdesk says AMGN’s Imdelltra in combination with Imfinzi demonstrated landmark improvement in overall survival in first-line extensive-stage small cell lung cancer.
EQUITY | Sep 08, 2026, 01:02 PM UTC
L
BMO downgrades Amgen to Market Perform from Outperform
BMO Capital downgraded Amgen to Market Perform from Outperform, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 12:25 PM UTC
L
Cantor Fitzgerald maintains AMGN $400 price target
Cantor Fitzgerald maintained its $400.00/share price target for AMGN, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 11:09 AM UTC
H
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market — Barrons.com
By George GloverStock futures were dropping on Tuesday as oil prices neared $100 a barrel, bolstering the case for the Federal Reserve to hike interest rates next week.Artificial-intelligence stocks were rising despite t
MACRO | Sep 08, 2026, 11:06 AM UTC
M
Amgen inherits a higher proof bar after rival trial outcome
Amgen is facing a tougher burden of proof as its shares stood at $437.23, following Novartis’s Phase 3 pelacarsen trial results that lowered Lp(a) but failed to cut major cardiovascular events.
EQUITY | Sep 07, 2026, 09:46 PM UTC
M
Novartis shares slide after-hours after heart-trial fails to cut events
Novartis shares sank after-hours after a heart-disease trial failed to show that lowering an inherited risk factor prevented heart attacks and strokes. NVS closed at $159.99, then slipped as much as about 7% after hours.
EQUITY | Sep 04, 2026, 10:52 PM UTC
L
Wells Fargo keeps Amgen at equal weight; raises price target to $435
Wells Fargo maintained an equal-weight rating on Amgen and raised its price target to $435.00 per share from $400.00, according to Benzinga.
EQUITY | Sep 04, 2026, 06:48 PM UTC
L
AMGN - AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
AMGN - AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
EQUITY | Sep 02, 2026, 08:02 PM UTC
L
Amgen to present at 2026 Wells Fargo Healthcare Conference
Amgen will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. CFO Thomas Dittrich and Paul Burton, M.D., Ph.D. are listed to participate.
EQUITY | Sep 02, 2026, 08:01 PM UTC
M
Amgen hit as UK suspends Tavneos for new patients
Amgen faces a widening regulatory threat to rare-disease drug Tavneos. The U.K. suspended use for new patients and set a path toward full withdrawal in March 2027, after similar Europe action and proposed U.S. withdrawal
EQUITY | Sep 02, 2026, 03:16 PM UTC